Introduction
T cells require two signals to become activated and cells for proliferation and IL-2 production. It is probably for this reason that a mouse genetically deficient in B7-1 was differentiate. Signal one occurs when the TCR complex recognizes antigen bound to MHC molecules on the surface of essentially immuno-competent (4). On the other hand, T cells from a mouse deficient for CD28 could not produce IL-2 antigen-presenting cells (APC). This interaction determines the antigen specificity of the immune response. Signal after stimulation with the mitogenic lectin concanavalin A, suggesting that co-stimulation through this molecule is critical two, termed co-stimulation, is provided by accessory molecules on the APC and T cell, and appears to be for IL-2 production (9) . Recent evidence suggests that costimulation provided by B7 molecules through CTLA-4 is also necessary for functional T cell activation. While there are several TCR-ligand pairs which can provide co-stimulation, important in several different methods used to establish peripheral tolerance in vivo (10) (11) (12) (13) . Thus, by the signal provided by the B7 family of surface molecules with its receptors on T cells, CD28 and CTLA-4, appear to engaging either CD28 or CTLA-4, B7 molecules themselves are able to either enhance or inhibit immune responses. predominate in T cell activation (1-3). At least two members of the B7 family have been defined B7-1 (CD80) and B7-2
During recent years the understanding of immunological mechanisms involved in autoimmune demyelination has (CD86) (4-8). These molecules, although having modest homology, are each capable of providing co-stimulation to T been greatly advanced by the study of experimental auto-immune encephalomyelitis (EAE), an animal model of multiple IgG was purchased from Jackson ImmunoResearch (West Grove, PA). sclerosis. EAE can be induced either by immunization of susceptible animals with components of myelin or by the Antigenic challenges adoptive transfer of CD4 ϩ T cells specific for myelin antigens (14, 15) . These encephalitogenic T cells produce lymphoAt day 0, mice were immunized s.c. with MBP Ac1-11 (30 µg) toxin and IFN-γ, but little IL-4 (14, 15) . B7 co-stimulation can in incomplete Freund's adjuvant (IFA; Difco, Detroit, MI) in the contribute to IFN-γ secretion by T h 1 clones (16) . Much has primed group. Mice in the i.v. tolerized group received MBP been learned about the role of co-stimulation in EAE using a Ac1-11 (200 µg) in PBS (0.2 ml). soluble fusion protein, CTLA-4-Ig, which can prevent the In vivo antibody treatments interaction between B7 and CD28 or CTLA-4 (17). Our laboratory has examined the role of B7:CD28/CTLA-4 interAnti-CTLA-4 mAb (200 µg) or control hamster IgG (200 µg) action in the induction of EAE (18, 19) . In the adoptive transfer were given on days -1, 0 and ϩ1 relative to i.v. antigen model of EAE, CTLA-4-Ig was able to inhibit the administration. proliferation and IL-2 production of MBP-specific lymph node
Lymphocyte proliferation cells (LNC) during activation in vitro, resulting in reduced clinical disease upon subsequent transfer. Thus, B7-mediated Proliferative responses by LNC and splenocytes were co-stimulation was found to be an important factor in determinmeasured 3 and 10 days after antigenic challenge. Results ing encephalitogenicity.
shown are representative of two to three experiments. Cells Studies by our laboratory have demonstrated that high-dose (2ϫ10 5 /well) were incubated with MBP or media alone as i.v. antigen therapy results in the elimination of MBP-specific, indicated. Cultures were maintained in 96-well, flat-bottom autoreactive T cells (20, 21 Measurement of cytokine production responses in the spleen.
We have previously used T cells from MBP-specific TCR An IL-2-dependent cell line, CTLL.EV (27) , was generously transgenic mice to follow the fate of encephalitogenic T cells provided by Dr Jonathan Katz (Washington University in vivo following i.v. tolerance (20, 22) . In this study, we used 
Induction of EAE Methods
Ten days after receiving i.v. antigen and i.p. antibody, mice Mice were immunized with MBP Ac1-11/complete Freund's adjuvant (CFA) (200 µg) s.c. over the flanks. Mice were Transgenic mice bearing the rearranged V β 8.2 gene specific examined daily for signs of disease and graded on the for MBP Ac1-11 on the B10.PL background were provided following scale: 0, no abnormality; 1, a limp tail; 2, moderate by Dr Joan Goverman (University of Washington, Seattle, hind limb weakness; 3, severe hind limb weakness; 4, com-WA) (22) (23) (24) . These mice were bred and maintained in our plete hind limb paralysis; 5, quadriplegia or premoribund animal colony at Washington University School of Medicine state (19) (20) (21) 28) . in compliance with the Animal Studies Committee. All mice were 6-8 weeks of age when experiments were initiated.
Results

Reagents
V β 8.2 TCR transgenic mice have increased frequency of MBPWhole MBP was prepared from guinea pig spinal cords as specific T cells previously described and purity assessed by SDS-PAGE (25). MBP peptide Ac1-11 was synthesized by the Protein To determine if naive B10.PL mice transgenic for the V β 8.2 TCR derived from an encephalitogenic T cell clone have a Chemistry Laboratory at Washington University School of Medicine with purity assessed by mass spectrometry. Hamster higher frequency of MBP-specific T cells than wild-type B10.PL mice, a proliferation assay was performed. LNC and anti-mouse CTLA-4 mAb UC10-4F10 was provided by Dr Jeff Bluestone (University of Chicago, Chicago, IL) (26) . Hamster splenocytes from V β 8.2 TCR transgenic mice demonstrated were examined at 3 and 10 days post antigen administration. Three days following administration of i.v. MBP Ac1-11, a decreased proliferative response was observed in LNC, which was partly reversed by anti-CTLA-4 administration ( Fig. 1) , similar to prior observations (10) . Surprisingly, at day 10 following i.v. administration of antigen, anti-CTLA-4 accentuated inhibition of MBP-specific proliferation by LNC (Fig. 2) , while a single injection of MBP i.v. did not demonstrate a tolerogenic response at 10 days as deter- IFN-γ production ( Fig. 3B and C) . IL-4 production was not significantly affected by the different protocols (Fig. 3D ). At 10 days following i.v. antigen administration, a decrease in MBP-specific splenocyte proliferation was observed and anti-CTLA-4 again resulted in further inhibition of proliferation (Fig. 4A ). Cytokine (IL-2, IL-4 and IFN-γ) production at 10 days following i.v. antigen administration was all reduced compared to naive splenocytes ( Fig. 4B and D) . Antigen administered i.v. did not appear to induce T h 2 differentiation of antigen-specific T cells in the spleen, but rather anergy, which was demonstrated by decreased proliferation, IL-2 and IFN-γ production. (Table 1) . Examination of the proliferative response to MBP from draining a robust proliferative response to MBP compared to cells from wild-type mice (29) . Limiting dilution analysis estimated LNC showed that the dramatic reduction in proliferative response observed 10 days after challenge with i.v. antigen the frequency of MBP-specific cells to be~1/163,000 (data not shown), which is significantly higher than the frequency and anti-CTLA-4 was abrogated in an inflammatory environment (Fig. 5 ). in naive, wild-type B10.PL mice (Ͻ1/830,000 ) (data not shown). Due to the high frequency of naive MBP-specific T
The effects of anti-CTLA-4 administration on tolerance induccells in these mice, they provided an informative system for tion and susceptibility to EAE studying tolerance induction in the EAE model and were used for all subsequent experiments.
Because 100% of immunized B10.PL V β 8.2 TCR transgenic mice develop EAE when challenged s.c. with MBP Ac1-11/ Tolerance induction after i.v. administration of antigen CFA (Table 1) , we decided to examine the effects of i.v. antigen administration on EAE susceptibility. Mice were tolerized with Previously anti-CTLA-4 has been reported to block tolerance induction by i.v. administration of antigen (OVA i.v. administration of MBP Ac1-11 as before and reimmunized 10 days later with 200 µg MBP Ac1-11/CFA s.c. Mice were peptide 323-339) (30) . To determine if i.v. tolerance induction to a self-antigen was dependent on CTLA-4 engagement, then observed for clinical signs of EAE. These mice developed severe EAE, irrespective of anti-CTLA-4 administration (Table  we compared Discussion inhibitory effect on the induction of EAE, at least when given as a single injection of antigen. In the present study, we examined the effect of i.v. antigen A recent study has examined the role of IL-12 and B7-administration on the effect of cytokine production, lymphomediated co-stimulation in T cell anergy in vivo (30) . These cyte proliferation and ability to induce the organ-specific authors demonstrated that high doses of antigen in the autoimmune disorder, EAE. In particular, we also addressed absence of adjuvant could be immunogenic in the presence the role of CTLA-4 in these processes. Immune responses of IL-12 and anti-CTLA-4. Furthermore, they demonstrated induced by a protein antigen can be suppressed when that that IL-12 was crucial for T h 1 differentiation, while anti-CTLAsame antigen is administered i.v. to adult animals. This form 4 was important in establishing a proliferative response. of tolerance, sometimes referred to as 'high antigen dose Our observation that anti-CTLA-4 seems to dramatically suppression' or 'high zone tolerance', involves extrathymic enhance tolerance in splenocytes when administered with i.v. mechanisms (31) .
antigen after 10 days is intriguing. It has been shown that Consistent with our prior observations, a single injection of when anti-CTLA-4 is administered with antigen, in vivo clonal i.v. antigen was unable to block the induction of EAE (Table  expansion is greatly enhanced (30) . It is likely that following 1). However, based on the readouts of proliferation and i.v. administration of MBP in the V β 8.2 TCR transgenic mouse, cytokine production, it appeared that a significant proportion that a similar expansion would take place. These T cells may of antigen-specific T cells had been anergized or deleted.
be very susceptible to antigen-induced cell death upon This is consistent with recent observations that clonal anergy subsequent stimulation in vitro, producing the types of can contribute to tolerance by limiting the size of the antigenobservations shown in Figs 1-4 . On the other hand, it may specific responder population, but it may not disrupt its be that the expansion noted after 3 days cannot be sustained effector function (32) . Another possibility is that i.v. antigen in the absence of adjuvant, resulting in our observations administration may activate a small preprimed population of T noted 10 days after antigen challenge. However, as noted cells, which are then capable of causing EAE when challenged above, some MBP-specific T cells may have differentiated with MBP Ac1-11/CFA. Thus, despite dramatically affecting into T h 1 effector cells following i.v. antigen administration and the MBP-specific proliferative response and IL-2 production in response to antigen, i.v. tolerance was unable to have an these cells could then participate in the encephalitogenic e 200 µg MBP Ac1-11 in PBS was administered on day 0. Mice were injected with 200 µg anti-CTLA-4 or control antibody on day -1. Mice were also challenged with CFA s.c. over the flanks.
f Mean day of onset of EAE Ϯ SEM following immunization, which occurred 10 days after initial i.v. antigen administration.
response (Table 1) . MBP-specific T cells which had been the case in our system, i.v. antigen with CFA and anti-CTLA-4 does not result in an encephalitogenic response (Table 1) . activated may have trafficked out of the peripheral lymph nodes, which are normally the site for recruitment of LIt will be interesting to determine whether the combination of i.v. antigen, anti-CTLA-4 and CFA affects the ability of selectin ϩ naive T cells. Prior studies have also demonstrated that i.v. antigen can be immunogenic when administered with encephalitogenic T cells to home to the CNS. Overall, our findings suggest that the route of antigen anti-CTLA-4 in an inflammatory environment elicited by CFA (30) . Our studies would suggest that while this may also be administration is very important in determining the phenotype CTLA-4 administration (29) . In addition, these studies on i.v. tolerance point out that in vitro assays on antigen-specific References cell populations may not necessarily reflect what will happen with regard to an encephalitogenic response. Our studies
